Literature DB >> 31828078

Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation.

Davide Spica1, Till Junker2, Michael Dickenmann1, Stefan Schaub1,3,4, Jürg Steiger1,3, Tanja Rüfli5, Jörg Halter2, Helmut Hopfer6, Andreas Holbro2,5, Patricia Hirt-Minkowski1.   

Abstract

We report the effectiveness of daratumumab, a human IgGκ monoclonal antibody targeting CD38 on plasma cells, for therapy-refractory antibody-mediated rejection (AMR) due to blood group antibodies in a 59-year-old man who received a living ABO-incompatible kidney transplantation. Standard treatment options for AMR due to blood group antibodies including immunoadsorption, lymphocyte depletion with anti-human T-lymphocyte globulins, intravenous methylprednisolone pulses and eculizumab limited tissue injury, however failed to sufficiently suppress blood group antibody production. After administration of daratumumab as a rescue therapy, blood group antibody titers decreased and remained at low levels without further immunoadsorption and allowed kidney graft function to recover.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  ABO-incompatible kidney transplantation; Anti-rejection therapy; Antibody-mediated rejection; Daratumumab

Year:  2019        PMID： 31828078      PMCID： PMC6902247          DOI： 10.1159/000503951

Source DB:  PubMed          Journal:  Case Rep Nephrol Dial


  7 in total

Review 1.  Antibody-mediated rejection: prevention, monitoring and treatment dilemmas.

Authors:  Sonia Rodriguez-Ramirez; Ayman Al Jurdi; Ana Konvalinka; Leonardo V Riella
Journal:  Curr Opin Organ Transplant       Date:  2022-08-11       Impact factor: 2.269

Review 2.  Immunotherapy for Refractory Autoimmune Encephalitis.

Authors:  Jiawei Yang; Xueyan Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 3.  Innovative immunosuppression in kidney transplantation: A challenge for unmet needs.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Transplant       Date:  2022-03-18

4.  Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.

Authors:  Katharina A Mayer; Klemens Budde; Philip F Halloran; Konstantin Doberer; Lionel Rostaing; Farsad Eskandary; Anna Christamentl; Markus Wahrmann; Heinz Regele; Sabine Schranz; Sarah Ely; Christa Firbas; Christian Schörgenhofer; Alexander Kainz; Alexandre Loupy; Stefan Härtle; Rainer Boxhammer; Bernd Jilma; Georg A Böhmig
Journal:  Trials       Date:  2022-04-08       Impact factor: 2.279

5.  Daratumumab for immune thrombotic thrombocytopenic purpura.

Authors:  Jana van den Berg; Johanna A Kremer Hovinga; Claudia Pfleger; Inga Hegemann; Gregor Stehle; Andreas Holbro; Jan-Dirk Studt
Journal:  Blood Adv       Date:  2022-02-08

Review 6.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

Review 7.  HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.

Authors:  Nizar Joher; Marie Matignon; Philippe Grimbert
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.